Holen Sie sich die Stockscreener-App
1.21
5.22%
0.06
Handel nachbörslich:
1.22
0.01
+0.83%
Schlusskurs vom Vortag:
$1.15
Offen:
$1.16
24-Stunden-Volumen:
897.85K
Relative Volume:
1.69
Marktkapitalisierung:
$139.48M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.33M
KGV:
-4.2847
EPS:
-0.2824
Netto-Cashflow:
$-17.65M
1W Leistung:
-1.63%
1M Leistung:
+17.48%
6M Leistung:
+27.27%
1J Leistung:
-18.24%
1-Tages-Spanne:
$1.14
$1.24
1-Wochen-Bereich:
$1.1106
$1.25
52-Wochen-Spanne:
$0.88
$1.71
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.21 | 133.14M | 0 | -26.33M | -17.65M | -0.2824 |
TAK
Takeda Pharmaceutical Co Adr
|
17.25 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.11 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.41 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.03 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
525.82 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-26 | Eingeleitet | ROTH MKM | Buy |
| 2024-04-22 | Eingeleitet | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Aktie (CRDL) Neueste Nachrichten
Cardiol Therapeutics Inc (CRDL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
What's Going On With Cardiol Therapeutics Inc Class A Stock Tuesday? - Wealth Awesome
TradingKey - TradingKey
CRDL|Cardiol Therapeutics Inc|Price:1.180|Chg%:-0.050 - TradingKey
Cardiol Therapeutics Inc (CRDL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cardiol Therapeutics Inc (CRDL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cardiol Therapeutics Inc (CRDL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cardiol Therapeutics Inc. Class A Revenue Breakdown – SWB:CT9 - TradingView
Why Cardiol Therapeutics Inc Class A stock is sliding today - Wealth Awesome
Cardiol Therapeutics (CRDL) Gains 4.13% as Bullish Momentum Builds Above $1.23 SupportDouble EMA - dars.gov.et
What's Going On With Cardiol Therapeutics Inc Class A Stock Monday? - Wealth Awesome
CRDL Stock Price, Quote & Chart - ChartMill
Why Cardiol Therapeutics Inc Class A stock is skyrocketing today - Wealth Awesome
Cardiol Therapeutics (TSX:CRDL) Expands Visibility Across Healthcare Sector - Kalkine Media
Why Cardiol Therapeutics Inc Class A stock is rising today - Wealth Awesome
Cardiol Therapeutics Publishes Recurrent Pericarditis Phase II Data - t.co
H.C. Wainwright reiterates Cardiol Therapeutics stock Buy rating at $9 - Investing.com
H.C. Wainwright reiterates Cardiol Therapeutics stock Buy rating at $9 By Investing.com - Investing.com Nigeria
Cardiol Therapeutics’ Phase II Pericarditis Data in JAHA Bolsters Near-Complete Phase III MAVERIC Trial - TipRanks
Cardiol Publishes Phase II MAVERIC Data in the Journal of the American Heart Association - the deep dive
Cardiol publishes phase II pericarditis study in medical journal By Investing.com - Investing.com South Africa
CRDL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $9 - GuruFocus
Stocks in play: Cardiol Therapeutics Inc. - Yahoo! Finance Canada
Cardiol Therapeutics Inc. - Baystreet.ca
Cardiol publishes phase II pericarditis study in medical journal - Investing.com
Cardiol Therapeutics (NASDAQ: CRDL) publishes Phase II pericarditis data as Phase III nears full enrollment - Stock Titan
Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association - PR Newswire
CRDL SEC FilingsCardiol Therapeu 10-K, 10-Q, 8-K Forms - Stock Titan
Cardiol Therapeutics (CRDL) to Attend B. Riley Securities Summit in Boston - GuruFocus
Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit - 富途牛牛
Cardiol Therapeutics to Highlight CardiolRx Programs at B. Riley Mind, Muscle & Vision Summit - TipRanks
Cardiol Therapeutics (CRDL) to present CardiolRx™ pipeline at B. Riley Mind, Muscle & Vision Summit - Stock Titan
Why Cardiol Therapeutics Inc Class A stock is plummeting today - Wealth Awesome
ETFs Investing in Cardiol Therapeutics Inc. Class A Stocks - TradingView
Why Cardiol Therapeutics Inc Class A stock is gaining today - Wealth Awesome
Why Cardiol Therapeutics Inc Class A stock is tanking today - Wealth Awesome
CRDL Should I Buy - Intellectia AI
CRDL Q1 2026 Earnings: Narrower-than-Expected Loss as Cardiol Therapeutics Advances PipelineReturn On Equity - dars.gov.et
CRDL Q1 2026 Earnings: Narrower-Than-Expected Loss as Company Advances Clinical PipelineEstimate Uncertainty - DonanımHaber
CRDL Q1 2026 Earnings: Narrower-than-Expected Loss Signals Steady Clinical ProgressGAAP Earnings Report - dars.gov.et
Enterprise value to revenue forward of Cardiol Therapeutics Inc. – BOATS:CRDL - TradingView
Price to earnings forward of Cardiol Therapeutics Inc. Class A – TSX:CRDL - TradingView
Enterprise value to revenue forward of Cardiol Therapeutics Inc. Class A – TSX:CRDL - TradingView
Cardiol Therapeutics Inc. Class A Actuals & Estimates (TSX:CRDL) - TradingView
Cardiol Therapeutics Inc. Class A Actuals & Estimates (NEO:CRDL) - TradingView
CRDL Forecast — Price Target — Prediction for 2027 - TradingView
Cardiol Therapeutics Shareholders Back Board Slate and Auditor at 2026 AGM - TipRanks
A2PA9E Forecast — Price Target — Prediction for 2027 - TradingView
Strong shareholder support at Cardiol Therapeutics (CRDL) 2026 AGM as all directors elected - Stock Titan
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders - Finansavisen
Finanzdaten der Cardiol Therapeutics Inc-Aktie (CRDL)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.50%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):